Improvement of steatohepatitis during therapy with olaparib in metastatic BRCA1-mutated breast cancer: A case report suggesting new opportunities of PARP inhibitors
Metabolic dysfunction-associated steatotic liver disease (MASLD) is commonly diagnosed in patients with metastatic breast cancer (mBC). Poly(ADP-ribose)polymerase inhibitors (PARPi) improve outcomes in BRCA-mutated mBC by blocking DNA-repair mechanisms. Preclinical studies suggest that PARPi may also benefit MASLD by r...